stockrow
Friday 6 November 2026
Export LTRN’s income statement to Excel — free account
Lantern Pharma Inc.
LTRN Healthcare Biotechnology
- EPS
- −42.5%
- Free cash flow
- +25.3%
Quarter to June 2026, against a year earlier
0.56
0.03
+5.66%
Follow LTRN
Alert me
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.68 | 2.52 | 36.64 | 31.26 | 20.99 | 16.18 | 5.83 | 2.40 |
Net Debt/EBITDA |
— | 0.26 | 0.51 | 3.24 | 5.68 | 3.89 | 2.29 | 1.07 | 0.56 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.74 | 0.88 | 0.96 | 0.86 | 0.90 | 0.90 | 0.86 | 0.92 |
Capex/Depreciation |
— | 0.00 | (3.56) | (4.74) | (0.11) | (0.30) | 0.12 | 0.06 | 0.01 |
| — | (479.49%) | (661.82%) | (57.25%) | (27.09%) | (22.35%) | (32.93%) | (66.93%) | (123.51%) | |
| — | (767.63%) | (257.99%) | (54.22%) | (26.22%) | (21.48%) | (31.15%) | (60.04%) | (93.53%) | |
ROIC |
— | 0.00% | 0.00% | (638.75%) | (930.33%) | (2,999.83%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 855.92% | (322.77%) | (29.98%) | (17.56%) | (25.48%) | (39.20%) | (99.13%) | (270.30%) |
Average Days of Receivables |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.20) | (1.08) | (1.32) | (0.97) | (1.18) | (1.32) | (1.66) | (1.44) |
Cash per Share |
— | 0.07 | 0.62 | 4.47 | 6.49 | 5.14 | 3.81 | 2.23 | 0.93 |
Shareholders Equity per Share |
— | (0.03) | 0.48 | 4.58 | 6.56 | 5.16 | 3.77 | 1.97 | 0.60 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.03) | 0.48 | 4.58 | 6.56 | 5.16 | 3.77 | 1.97 | 0.60 |
Free Cash Flow |
— | (1.27) | (2.13) | (5.67) | (10.61) | (12.80) | (14.37) | (17.83) | (15.68) |
Working Capital |
— | (0.21) | 0.74 | 19.68 | 70.39 | 55.92 | 40.66 | 20.92 | 6.30 |
Capital Expenditures |
— | — | (0.01) | (0.02) | (0.02) | (0.03) | (0.02) | (0.01) | 0.00 |
Net Current Asset Value |
— | (0.21) | 0.74 | 19.58 | 70.34 | 55.92 | 40.60 | 20.86 | 6.30 |
| Other line items | |||||||||
Quick Ratio |
— | 0.68 | 2.52 | 34.82 | 30.40 | 19.92 | 15.42 | 5.54 | 2.25 |
Depreciation/Fixed assets |
— | (0.53) | 0.18 | 0.16 | 4.88 | 1.92 | (3.04) | (4.67) | (5.61) |
Cash ROIC |
— | (522.39%) | (98.08%) | (14.52%) | (7.45%) | (11.45%) | (17.47%) | (39.44%) | (94.15%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | — | — | — |
Accounts Payable Turnover |
— | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | (17,023.60) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.20) | (1.08) | (1.31) | (0.97) | (1.18) | (1.32) | (1.66) | (1.44) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | — | — | 0.39 | — | — | — |
Average Payables |
— | 0.30 | 0.30 | 0.52 | 1.36 | 2.46 | 2.63 | 3.32 | 4.28 |
Average Assets |
— | 0.22 | 0.94 | 10.90 | 47.16 | 66.39 | 51.24 | 34.61 | 18.30 |
Average Common Equity |
— | 0.36 | 0.37 | 10.32 | 45.64 | 63.80 | 48.47 | 31.05 | 13.86 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates